Home » Health and Fitness Articles » Personal Injury Firm Represents Diabetics With Actos Lawsuit Claims
Personal Injury Firm Represents Diabetics With Actos Lawsuit Claims
Personal injury law firm Goldberg & Osborne announces that it is now taking claims for diabetes patients who developed bladder cancer after taking Actos (pioglitazone) to manage their blood glucose levels.
PHOENIX, AZ, August 13, 2011 /Health and Fitness PR News/ -- Personal injury law firm Goldberg & Osborne announces that it is now taking claims for diabetes patients who developed bladder cancer after taking Actos (pioglitazone) to manage their blood glucose levels.
Sales of Actos have already been suspended in France and restricted in Germany. However, even though the U.S. Food and Drug Administration released a safety announcement about the drug's side effect of bladder cancer on June 15, 2011, the drug is still being prescribed in the U.S.A. The FDA recommends physicians not prescribe the drug to patients who are already at risk for bladder cancer.
Several claims against Actos manufacturer, Takeda Pharmaceuticals, have already been launched.
In some severe cases, Actos side effects have been fatal, leaving families with expensive medical and funeral costs. However, these families may be entitled to compensation from Takeda Pharmaceuticals as an increased risk of bladder cancer was not previously listed as a side effect.
Goldberg & Osborne encourages anyone who has been diagnosed with bladder cancer and has taken Actos to contact their office for a free consultation. The number (800) 549-8048 is toll free. You can also visit our website for more information: http://actoslawyer.com.
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com |
|
|
Press Release Contact Information:
Rob Lindley
Goldberg & Osborne
Attorney
4423 E. Thomas Rd., Suite 3,
Phoenix, AZ
USA 85018
Voice: 602-808-6750
Website: Visit Our Website |
|
|
|
|
| HEALTH AND FITNESS ARCHIVE SEARCH |
|
|
| |
| SUBMIT HEALTH AND FITNESS NEWS |
|
|
| |
|
|
Advertise With Us |
About Us |
Contact Us